Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID A SAPERSTEIN

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1508946625
CMS profile
203985
Location
BELLEVUE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$4,921.42

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $4,860.00 3
Food and Beverage $61.42 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Regeneron Healthcare Solutions, Inc. $4,921.42 4

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID A SAPERSTEIN

NPI 1508946625 · CMS profile ID 203985

Allopathic & Osteopathic Physicians / Ophthalmology

BELLEVUE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508946625?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID A SAPERSTEIN, NPI 1508946625, CMS profile ID 203985. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508946625?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). DAVID A SAPERSTEIN, NPI 1508946625, CMS profile ID 203985. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508946625?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
DAVID A SAPERSTEIN, NPI 1508946625, CMS profile ID 203985, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1508946625?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $4,921.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $2,160.0012/10/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724452081 CMS
Regeneron Healthcare Solutions, Inc. $1,080.0010/08/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724452079 CMS
Regeneron Healthcare Solutions, Inc. $1,620.0005/28/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724452077 CMS
Regeneron Healthcare Solutions, Inc. $61.4202/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724452073 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,404.95 7
PY2020 $4,921.42 4
PY2021 $3,310.83 5
PY2022 $3,786.65 13
PY2023 $8,227.58 15
PY2024 $23,313.03 26
PY2025 $4,301.61 19

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $49,152.74 22
PY2024 Principal investigator $41,747.06 19
PY2023 Principal investigator $51,577.99 16
PY2022 Principal investigator $38,480.56 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

16 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Apellis Pharmaceuticals, Inc. $260.00 12/20/2023 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1056316355
Principal investigator 1 Astellas Pharma Global Development $8,761.50 12/01/2023 Non-covered Recipient Entity
Pacific Northwest Retina
An Open-Label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients with Geographic Atrophy who Previously Completed Phase 3 Study ISEE2008 (GATHER2) No dispute reported 06/30/2026 1022255843
Principal investigator 1 Astellas Pharma Global Development $6,100.00 11/29/2023 Non-covered Recipient Entity
Pacific Northwest Retina
An Open-Label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients with Geographic Atrophy who Previously Completed Phase 3 Study ISEE2008 (GATHER2) No dispute reported 06/30/2026 1022255865
Principal investigator 1 Astellas Pharma Global Development $400.00 11/15/2023 Non-covered Recipient Entity
Pacific Northwest Retina
An Open-Label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients with Geographic Atrophy who Previously Completed Phase 3 Study ISEE2008 (GATHER2) No dispute reported 06/30/2026 1022255855
Principal investigator 1 Apellis Pharmaceuticals, Inc. $7,019.10 09/28/2023 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1056311057
Principal investigator 1 Apellis Pharmaceuticals, Inc. $315.00 09/25/2023 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1056309603
Principal investigator 1 Apellis Pharmaceuticals, Inc. $39.54 09/21/2023 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1056306879
Principal investigator 1 Apellis Pharmaceuticals, Inc. $807.15 09/21/2023 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1056324643
Principal investigator 1 Astellas Pharma Global Development $4,152.60 08/22/2023 Non-covered Recipient Entity
Pacific Northwest Retina
An Open-Label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients with Geographic Atrophy who Previously Completed Phase 3 Study ISEE2008 (GATHER2) No dispute reported 06/30/2026 1022255877
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,672.00 07/31/2023 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1056315141
Principal investigator 1 Apellis Pharmaceuticals, Inc. $304.00 04/17/2023 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1056313051
Principal investigator 1 Apellis Pharmaceuticals, Inc. $9,998.10 04/17/2023 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1056314409
Principal investigator 1 Apellis Pharmaceuticals, Inc. $65.00 04/03/2023 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1056325095
Principal investigator 1 Apellis Pharmaceuticals, Inc. $65.00 02/28/2023 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1056307599
Principal investigator 1 Apellis Pharmaceuticals, Inc. $439.00 02/28/2023 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1056321919
Principal investigator 1 Apellis Pharmaceuticals, Inc. $9,180.00 02/13/2023 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1056325719